Free Trial
NASDAQ:RGNX

REGENXBIO (RGNX) Stock Price, News & Analysis

REGENXBIO logo
$8.59
-0.25 (-2.83%)
(As of 10/31/2024 ET)

About REGENXBIO Stock (NASDAQ:RGNX)

Key Stats

Today's Range
$8.57
$8.98
50-Day Range
$8.84
$12.95
52-Week Range
$8.56
$28.80
Volume
501,705 shs
Average Volume
593,309 shs
Market Capitalization
$423.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.45
Consensus Rating
Moderate Buy

Company Overview

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

REGENXBIO Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
92nd Percentile Overall Score

RGNX MarketRank™: 

REGENXBIO scored higher than 92% of companies evaluated by MarketBeat, and ranked 119th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    REGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    REGENXBIO has only been the subject of 4 research reports in the past 90 days.

  • Read more about REGENXBIO's stock forecast and price target.
  • Earnings Growth

    Earnings for REGENXBIO are expected to grow in the coming year, from ($4.66) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of REGENXBIO is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of REGENXBIO is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    REGENXBIO has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about REGENXBIO's valuation and earnings.
  • Percentage of Shares Shorted

    10.13% of the outstanding shares of REGENXBIO have been sold short.
  • Short Interest Ratio / Days to Cover

    REGENXBIO has a short interest ratio ("days to cover") of 9.9.
  • Change versus previous month

    Short interest in REGENXBIO has recently decreased by 6.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    REGENXBIO does not currently pay a dividend.

  • Dividend Growth

    REGENXBIO does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.13% of the outstanding shares of REGENXBIO have been sold short.
  • Short Interest Ratio / Days to Cover

    REGENXBIO has a short interest ratio ("days to cover") of 9.9.
  • Change versus previous month

    Short interest in REGENXBIO has recently decreased by 6.03%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    REGENXBIO has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for REGENXBIO this week, compared to 4 articles on an average week.
  • Search Interest

    3 people have searched for RGNX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $354,651.00 in company stock.

  • Percentage Held by Insiders

    13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about REGENXBIO's insider trading history.
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
REGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan Capital
Regenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMD
See More Headlines

RGNX Stock Analysis - Frequently Asked Questions

REGENXBIO's stock was trading at $17.95 on January 1st, 2024. Since then, RGNX stock has decreased by 51.8% and is now trading at $8.66.
View the best growth stocks for 2024 here
.

REGENXBIO Inc. (NASDAQ:RGNX) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.24. The company's quarterly revenue was up 11.6% compared to the same quarter last year.

Top institutional investors of REGENXBIO include Assenagon Asset Management S.A. (1.13%), Hennion & Walsh Asset Management Inc. (0.31%), Harbor Capital Advisors Inc. (0.07%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Kenneth T Mills, Kenneth T Mills, Curran Simpson, Vittal Vasista, Steve Pakola, Argeris N Karabelas and Allan M Fox.
View institutional ownership trends
.

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY) and Humana (HUM).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
344
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.45
High Stock Price Target
$52.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+309.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-263,490,000.00
Net Margins
-270.74%
Pretax Margin
-270.91%

Debt

Sales & Book Value

Annual Sales
$89.04 million
Book Value
$7.09 per share

Miscellaneous

Free Float
42,934,000
Market Cap
$426.56 million
Optionable
Optionable
Beta
1.21
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:RGNX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners